` RAPP (Rapport Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

RAPP
vs
S&P 500

Over the past 12 months, RAPP has underperformed S&P 500, delivering a return of -28% compared to the S&P 500's +13% growth.

Stocks Performance
RAPP vs S&P 500

Loading
RAPP
S&P 500
Add Stock

Performance Gap
RAPP vs S&P 500

Loading
RAPP
S&P 500
Difference
www.alphaspread.com

Performance By Year
RAPP vs S&P 500

Loading
RAPP
S&P 500
Add Stock

Competitors Performance
Rapport Therapeutics Inc vs Peers

S&P 500
RAPP
LLY
JNJ
NOVO B
ROG
Add Stock

Rapport Therapeutics Inc
Glance View

Market Cap
528.5m USD
Industry
Pharmaceuticals

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The firm focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. The company advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.

RAPP Intrinsic Value
8.36 USD
Overvaluation 43%
Intrinsic Value
Price
Back to Top